HANOVER, Md., March 24, 2016 -- The KEYW Holding Corporation (NASDAQ:KEYW), announced today it will host an Analyst & Investor Day on Thursday, April 7 from 9:30 AM to 2:15 PM at The Hotel at Arundel Preserve, 7795 Arundel Mills Blvd, Hanover, MD 21076. The meeting will be hosted by KEYW’s management team.
KEYW Analyst & Investor Day Agenda
9:30 AM – 10:00 AM Continental Breakfast
10:00 AM – 11:30 Technology Discussion and Product Demos
11:30 AM Break
11:45 AM – 1:15 PM Business Update Webcast
1:15 PM – 2:15 PM Lunch
2:15 PM Program End
To access the Business Update Webcast, please visit the Events and Presentations page of the KEYW Investor website at investors.keywcorp.com.
Institutional analysts and investors interested in attending the meeting should register by emailing [email protected]. The deadline to RSVP is April 1, 2016.
About KEYW
KEYW is a total solutions provider for the Intelligence Community's toughest challenges. We support the collection, processing, analysis and dissemination of information across the full life cycle of the Intelligence Community's mission. We employ and challenge the most talented professionals in the industry with solving such complex problems as preventing cyber threats, transforming data into intelligence, and combating global terrorism. For more information contact KEYW Corporation, 7740 Milestone Parkway, Suite 400, Hanover, Maryland 21076; Phone 443-733-1600; Fax 443-733-1601; E-mail [email protected]; or on the Web at www.keywcorp.com.
Forward-Looking Statements: Statements made in this press release that are not historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements about our future expectations, plans and prospects, and other statements containing the words "estimates," "believes," "anticipates," "plans," "expect," "will," "potential," "opportunities", and similar expressions. Our actual results, performance or achievements or industry results may differ materially from those expressed or implied in these forward-looking statements. These statements involve numerous risks and uncertainties, including but not limited to those risk factors set forth in our Annual Report on Form 10-K, dated and filed March 15, 2016 with the Securities and Exchange Commission (SEC) as required under the Securities Act of 1934, and other filings that we make with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements. KEYW is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Contact: Chris Donaghey 443-733-1600


Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs
CATL Stock Hits Record High After Q1 2025 Earnings Surge
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed
Want to cut your energy bills? Here’s how five experts are doing it
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 



